BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Autolus Therapeutics plc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Autolus Therapeutics plc's drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07053800-10865@assetmemo.bio
DTSTAMP:20261121T005930Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 2 readout est. (NCT070538
 00)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 2.\nStudy: Obe-cel i
 n Severe\, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus
  Nephritis (LN)\nEstimated primary completion: August 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07053800
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04404660-10865@assetmemo.bio
DTSTAMP:20261121T005930Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 1/2 readout est. (NCT0440
 4660)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 1/2\, Acute Lymphobl
 astic Leukemia.\nStudy: A Study of CD19 Targeted CAR T Cell Therapy in Adu
 lt Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaem
 ia (ALL)\nEstimated primary completion: 30 June 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04404660
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
